The schizophrenia PORT pharmacological treatment recommendations: Conformance and implications for symptoms and functional outcome

被引:33
作者
Buchanan, RW
Kreyenbuhl, J
Zito, JM
Lehman, A
机构
[1] Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA
[2] VA Capitol Network, Mental Illness Res Educ & Clin Ctr, Baltimore, MD USA
[3] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA
关键词
schizophrenia; antipsychotics; treatment recommendations; positive symptoms; depressive symptoms; social function; work function;
D O I
10.1093/oxfordjournals.schbul.a006927
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
This cross-sectional study examines conformance to four of the Schizophrenia Patient Outcomes Research Team (PORT) antipsychotic treatment recommendations, patient and treatment setting characteristics assocated with conformance, and the relationship of conformance with outcome. Two hundred twenty-four inpatients and 358 outpatients with schizophrenia underwent an interview and review of their medical records. Demographic, clinical, and role function data were collected. Almost all inpatients and outpatients with schizophrenia or schizoaffective disorder were prescribed an antipsychotic. The majority of inpatients were prescribed an antipsychotic within the recommended dose range, whereas the majority of outpatients were prescribed an antipsychotic either below or above the recommended dose range. There were no consistent relationships between patient, geographic, and treatment characteristics and antipsychotic dose. Patients treated with conventional antipsychotic doses below the recommended dose range had significantly better role function. Prospective longitudinal studies are required to delineate the factors that may underlie this relationship.
引用
收藏
页码:63 / 73
页数:11
相关论文
共 18 条
[1]  
Buchanan RW, 1998, AM J PSYCHIAT, V155, P751
[2]   Clozapine: Efficacy and safety [J].
Buchanan, RW .
SCHIZOPHRENIA BULLETIN, 1995, 21 (04) :579-591
[3]   Targeted maintenance treatment in schizophrenia - Issues and recommendations [J].
Buchanan, RW ;
Carpenter, WT .
CNS DRUGS, 1996, 5 (04) :240-245
[4]  
CARPENTER WT, 1990, AM J PSYCHIAT, V147, P1138
[5]   Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia [J].
Chen, RS ;
Nadkarni, PM ;
Levin, FL ;
Miller, PL ;
Erdos, J ;
Rosenheck, RA .
PSYCHIATRIC SERVICES, 2000, 51 (06) :791-794
[6]  
DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13
[7]  
DEROGATIS LR, 1977, J PSYCHOL, V3, P981
[8]   Conventional antipsychotic medications for schizophrenia [J].
Dixon, LB ;
Lehman, AF ;
Levine, J .
SCHIZOPHRENIA BULLETIN, 1995, 21 (04) :567-577
[9]  
KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789
[10]  
Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P1